SecBot SecBot
PRESS-RELEASE ·Filed Jul 6, 2026

PHVS

Pharvaris N.V.
BULLISH
Impact 6/10
Horizonmonths Processed4mo ago WireGlobeNewswire
Press release · M&A
Actionable Insight ▲ Bullish

Monitor FDA review milestones and any advisory committee meetings ahead of the April 2027 PDUFA date. The stock may re-rate on positive review updates or if competitor developments (e.g., Takeda's TAK-994) emerge. Near-term, the acceptance removes a key binary risk but approval remains the primary catalyst.

DirectionBullish
Confidencehigh
Horizonmonths

deucrictibant

◆ Mixed Named in this press release
Impact
Phase
Filed/PDUFA (IR capsule); Phase 3 (XR tablet)
Time to market
IR capsule could be approved by April 23, 2027 PDUFA date. XR tablet for prophylaxis would follow later, likely 2028+ if CHAPTER-3 is positive.
Next catalyst
None dated

What to watchTwo binary catalysts in the next ~9 months: CHAPTER-3 topline (Q3 2026) and the PDUFA decision on the IR capsule (April 23, 2027). The bigger swing factor near-term is CHAPTER-3, a positive readout would validate the larger prophylactic market opportunity, while a miss would severely dent the thesis given that sebetralstat (KalVista) already beat deucrictibant to market as the first oral on-demand HAE therapy.

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$33.22
T+0 close · Jul 6, 2026 · via day close
Latest settled
−4.49%
T+60 · $31.73
Vs SPY
−6.39%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 6 $33.22entry
  2. T+1 · 4mo ago +4.12%α +4.60% · $34.59
  3. T+5 · 4mo ago +5.57%α +5.08% · $35.07
  4. T+20 · 4mo ago −1.81%α −1.24% · $32.62
  5. T+60 · 7w ago −4.49%α −6.39% · $31.73
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pharvaris announced FDA acceptance of its New Drug Application (NDA) for deucrictibant immediate-release capsules for on-demand treatment of hereditary angioedema (HAE) attacks, with a PDUFA target action date of April 23, 2027. The NDA includes positive Phase 3 data (RAPIDe-3) showing rapid symptom relief and a well-tolerated safety profile. This milestone reduces regulatory uncertainty and positions deucrictibant as a potential first oral therapy for acute HAE attacks, though approval is still pending.

Key Facts

  • FDA accepted NDA for deucrictibant IR (20 mg) for on-demand treatment of HAE attacks
  • PDUFA target action date set for April 23, 2027
  • Phase 3 RAPIDe-3 study met primary and all 11 secondary endpoints with statistical significance
  • Median time to onset of symptom relief: 1.28 hours; median time to complete resolution: 11.95 hours
  • Deucrictibant granted orphan drug designation by FDA in 2022

Financial Impact

Not directly quantified; potential for significant revenue if approved as first oral on-demand HAE therapy, but commercial launch is contingent on FDA approval and market adoption

revenuemarket capitalization

Risk Factors

  • FDA may issue a Complete Response Letter (CRL) citing safety, efficacy, or manufacturing concerns
  • Competition from existing injectable therapies (e.g., icatibant, ecallantide) and potential oral entrants
  • Commercial execution risk if approved, given need to build sales infrastructure

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3322293

Track record

51 reports on PHVS

Performance horizon

14 of 17 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 16 of 18 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
  2. Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
  3. Nov 12, 20264d ago Press Release Bullish 7/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
  4. Nov 12, 20264d ago 6-K Neutral 4/10 No price data
  5. Nov 12, 20264d ago Press Release Neutral 5/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
  6. Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
  7. Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
  8. Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
  9. Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
  10. Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
Showing 10 of 51

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 6, 2026